UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This research study investigates the tolerability of substituting two cycles of chemotherapy into the standard pediatric acute myeloid leukemia (AML) chemotherapy treatment regimen for patients with newly diagnosed AML at intermediate-risk (IR) and high-risk (HR) of relapse. The goal is to achieve similar or better survival with chemotherapy cycles that are intensive but less likely to cause long-term complications. Patients will enroll on this trial at the end of their first induction cycle. The two cycles to be substituted are: * "Ida-FLA" (idarubicin+fludarabine/cytarabine) as Induction 2 * "VIA" (venetoclax+idarubicin+cytarabine) as Intensification 1 of the HR treatment regimen, and Intensification 2 of the IR treatment backbone. Researchers will evaluate side effects and outcomes for up to three years after enrollment. Participants will also have the opportunity to participate in optional research studies including patient surveys and blood and bone marrow sample testing.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 1 miesiąca do 30 lat
- •Nowo zdiagnozowana ostra białaczka szpikowa (AML) lub mieloidalny guz szpiku
- •Co najmniej 20% blasów (młodych komórek leukemicznych) w szpiku kostnym
- •Mniej niż 20% blasów w szpiku, ale z określonymi zmianami genetycznymi
- •Co najmniej 1000 leukemicznych komórek we krwi obwodowej, jeśli nie można wykonać punkcji szpiku
- •Ukończona pierwsza faza indukcji chemioterapii (DA10+GO)
- •Pośrednie lub wysokie ryzyko nawrotu choroby
✗ Disqualifies
- •Białaczka związana z wcześniejszym leczeniem nowotworów
Simplified criteria — AI translation
Trial details
- Minimum age
- 1 Month
- Maximum age
- 30 Years
- Last updated (source)
- August 24, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Texas Children's Cancer and Hematology Center
Houston, United States
Trial contact
Joanna S Yi, MD
Alexandra M Stevens, MD, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/25/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.